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Cartilage Oligomeric Matrix Protein (COMP): A Biomarker 
of Arthritis
Susan Tseng, A. Hari Reddi and Paul E. Di Cesare
Department of Orthopaedic Surgery, UC Davis Medical Center, Sacramento, California, 95817, U.S.A.
Abstract: Arthritis is a chronic disease with a signifi cant impact on the population. It damages the cartilage, synovium, 
and bone of the joints causing pain, impairment, and disability in patients. Current methods for diagnosis of and 
monitoring the disease are only able to detect clinical manifestations of arthritis late in the process. However, with the 
recent onset of successful treatments for rheumatoid arthritis and osteoarthritis, it becomes important to identify 
prognostic factors that can predict the evolution of arthritis. This is especially critical in the early phases of disease so 
that these treatments can be started as soon as possible to slow down progression of the disease. A valuable approach 
to monitor arthritis would be by measuring biological markers of cartilage degradation and repair to refl ect variations 
in joint remodeling. One such potential biological marker of arthritis is cartilage oligomeric matrix protein (COMP). 
In various studies, COMP has shown promise as a diagnostic and prognostic indicator and as a marker of the disease 
severity and the effect of treatment. This review highlights the progress in the utilization of COMP as a biomarker 
of arthritis.
Keywords: cartilage oligomeric matrix protein, arthritis, biomarker
Introduction
Arthritis is a longstanding, debilitating disease that results in serious repercussions on the population. 
It causes pain, impairment, and disability in patients with increasing injury to the cartilage, synovium, 
and bone of the joints. Existing methods to diagnose and to monitor the disease are based on late 
clinical manifestations of arthritis. However, with recent developments of successful treatments for 
rheumatoid arthritis and osteoarthritis, it becomes important to identify prognostic factors that can 
predict the evolution of arthritis. This would be of most value in the early phases of the disease so that 
treatments could be started expeditiously to help slow down progression of the disease. A possible 
approach to monitor arthritis would be to measure biological markers of cartilage repair and degradation 
to refl ect variations in joint remodeling. One such potential biological marker of arthritis is cartilage 
oligomeric matrix protein (COMP). This review highlights the progress in the utilization of COMP as 
a biomarker of arthritis. The disease of arthritis and the need for a biomarker will be discussed, along 
with COMP and its value as a prognostic and diagnostic indicator. COMP has also shown promise as 
a treatment monitor although its natural time course and variations will need to be delineated. The 
numerous studies on COMP in these different areas will be summarized in this review and the human 
studies are outlined in Table 1.
The Disease of Arthritis
As the leading cause of disability in the United States, arthritis is a chronic disease with a signifi cant 
impact on the population. Based on 2003–2005 data from the National Health Interview Survey (NHIS), 
an estimated one in fi ve or 46.4 million of U.S. adults have self-reported doctor-diagnosed arthritis. 
Almost 41% (19 million) of these 46 million adults report limitations in their usual activities due to 
their arthritis. In addition to activity limitations, 31% (8.2 million) of working age adults with doctor-
diagnosed arthritis report being limited in work activities. As the U.S. population ages, these numbers 
are likely to increase considerably. Each year, arthritis results in 750,000 hospitalizations and 36 million 
outpatient visits. In 2003, direct medical costs for arthritis were $81 billion while indirect costs were 
another $47 billion. This economic burden explains the increasing attention that is being directed to 
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arthritis and to fi nding pharmacological agents to 
help control the disease.
Arthritis refers to damage to the joints that can 
be caused by a variety of pathological processes, 
including osteoarthritis and rheumatoid arthritis. 
It manifests clinically as abnormal and degraded 
cartilage, infl amed and thickened synovial tissue, 
and altered bone structure resulting in pain, 
decreased mobility, impairment, and disability.1–3 
The diagnosis of arthritis is made based on the 
patient’s history, physical exam, and radiographs. 
However, plain radiographs only provide indirect 
information on cartilage, unlike the direct 
information it gives on bone. This is because 
damage to bone can be easily visualized in its 
actuality on a x-ray while injury to cartilage may 
only be gleaned from indirect cues such as joint 
space narrowing, bone erosions or osteophytes, 
osteopenia or sclerosis, and soft-tissue swelling.4,5 
Serial examinations over several years may be used 
for assessments of prognosis, treatment, and 
clinical outcomes. But, sensitivity to change is 
limited, and clinical manifestations of arthritis do 
not develop until late in the disease process. By 
then, the disease process of cartilage degeneration 
has progressed too far for the chondrocytes to be 
able to stop or reverse the joint disease, making it 
too late for early diagnosis and treatment.6–11 
Arthroscopy provides a direct and magnifi ed view 
of the cartilage surface, but this is an invasive 
technique that cannot be routinely applied to all 
patients. Laboratory markers such as erythrocyte 
sedimentation rate (ESR) and levels of C-reactive 
protein (CRP) provide useful information about 
the general infl ammation process in some patients, 
but these markers are not specifi c to infl ammation 
in joints and correlate poorly with cartilage damage 
at the individual level.12–15 Serum IgM rheumatoid 
factor (RF) and anti-cyclic citrullinated peptide 
antibodies (anti-CCP) have some diagnostic and 
prognostic value in the evaluation of rheumatoid 
arthritis, but positive results can occur with other 
diseases such as systemic lupus erythemato-
sus, Sjogren’s syndrome, cryoglobulinemia, 
polymyositis/dermatomyositis, psoriatic arthritis, 
scleroderma, polymyalgia rheumatica, viral 
infections, active tuberculosis, tumor, Lyme disease, 
autoimmune thyroid disease, and palindromic 
rheumatism.16–28 By the late stages of arthritis, 
treatment options are mainly palliative including 
medications, intra-articular injections, weight loss, 
ambulatory aids, orthotics, and physical therapy 
with surgical intervention being the last and most 
effective option for treatment.
A Biomarker for Arthritis
There have been recent developments of structure-
modifying agents that aim to prevent, delay and 
stabilize the progress of cartilage damage in 
osteoarthritis.29 Disease modifying anti-rheumatic 
drugs (DMARDs) that work to suppress the body’s 
immune system in rheumatoid arthritis to decrease 
pain and infl ammation and to preserve the structure 
and function of the joints have been successful in 
treatment30 This has lead to an increased interest 
in identifying a simple and reliable tool to measure 
cartilage metabolism and the effects of these 
treatments. It also becomes more important to 
identify prognostic factors that can predict the 
evolution of arthritis, especially in the early phases 
of disease so that these drugs can be started as soon 
as possible to slow down the progression of the 
disease. Given the limitations of the tools that are 
currently available for investigating arthritis, 
quantitative assessment of biological markers of 
cartilage degradation and repair would be a 
promising approach to predict quantitative and 
dynamic variations in joint remodeling. Since 
changes in the properties of joint cartilage and loss 
of matrix components are an integral part of the 
disease process, biological markers of cartilage 
metabolism could be used for the early subclinical 
diagnosis of arthritis. These markers are released 
into the synovial fl uid and eventually to other body 
fl uids, such as blood or urine, where they can be 
detected. Early diagnosis of impaired cartilage 
metabolism would enable early treatment, before 
there is marked loss of articular cartilage and 
radiographic changes. A biomarker would also be 
benefi cial to evaluate the severity of the disease, 
to assess and predict the progression of disease, 
and to monitor effects of treatment. Candidates for 
potential biologic markers of arthritis include 
matrix components, cytokines, growth factors, 
proteases, protease inhibitors, and serum autoan-
tibodies to cartilage components.31–43 Cartilage 
oligomeric matrix protein (COMP) is one such 
potential marker of arthritis that has shown promise 
as a biomarker of arthritis.
What is COMP?
Cartilage oligomeric matrix protein (COMP) is also 
known as thrombospondin 5. It is a 524 kDa 
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homopentameric, extracellular matrix glycoprotein 
member of the thrombospondin family of calcium-
binding proteins. COMP has fi ve identical subunits.44 
Each subunit consists of 755 amino acids, that 
interact close to their cysteine-rich aminoterminus, 
creating a fi ve-stranded coiled coil domain. This is 
followed by flexible regions of four EGF-like 
domains and eight TSP calmodulin-like repeats.45 
The carboxyterminal globular domain binds to 
collagens I, II, and IX and fi bronectin. The function 
of COMP remains unclear, but it may have a 
structural role in endochondral ossifi cation and in 
the assembly and stabilization of the extracellular 
matrix by its interaction with collagen fi brils and 
matrix components. COMP has been shown to 
infl uence the fi bril formation of collagens I and II 
by promoting early association of collagen 
molecules thereby accelerating fi brillogenesis with 
a distinct organization of the fi brils.46 It has also 
been shown that COMP binds to aggrecan, a major 
component of the cartilage extracellular matrix. This 
further supports the role of COMP in mediating the 
matrix molecule interactions needed to organize 
the cartilage matrix for its load bearing function.47 
The coiled-coil domain appears to play a role in the 
storage and delivery of hydrophobic cell-signaling 
molecules, such as Vitamin D.48,49 Originally 
described in cartilage, COMP has also been 
identifi ed in ligaments, meniscus, tendons, synovium, 
osteoblasts and vascular smooth muscle.50,51
COMP is considered a marker of cartilage 
breakdown, and is being studied as a biological 
marker in various uses. It has potential as a 
diagnostic and prognostic indicator and as a marker 
of the disease severity and the effect of treatment. 
The fi rst immunoassay for COMP was developed 
using COMP purified from bovine articular 
cartilage as an immunogen.52 Subsequently, 
numerous labs have developed both polyclonal and 
monoclonal antisera to COMP from a variety of 
species including human.53–57 With the advent of 
commercially available enzyme-linked immuno-
sorbent assay (ELISA) kits for COMP, there has 
been a new resurgence in investigating COMP as 
a biomarker. While these ELISA kits make it 
easier to quantitatively measure COMP levels, they 
do have some differences. These include the 
species type of COMP to be detected (human 
or animal), the ELISA method used (sand-
wich or competitive), the type of antibody used 
(monoclonal or polyclonal, from different species 
types), and the labeling of the detection antibody 
(alkaline phophatase labeled or biotin labeled with 
streptavidin-HRP conjugate).
COMP as a Diagnostic Indicator
COMP has been shown to be diagnostic of arthritis 
and to correlate with the disease severity. In patients 
with various types of arthritis, COMP levels were 
detected in all fl uids, but were ten times higher in 
synovial fl uid than in serum indicating preferential 
release from the affected joints. Levels did not 
correlate with ESR or other acute phase indicators 
of infl ammation.52 In the Johnston County Osteo-
arthritis Project, serum levels of COMP were 
elevated in participants with osteoarthritis (OA) and 
increased with the severity of the radiographic knee 
OA and the numbers of knees and hips that had OA 
on radiographs.58 Serum COMP levels were also 
higher in patients with bilateral versus unilateral hip 
involvement in patients with symptomatic hip OA.59 
Serum COMP levels have also been found to be 
higher in those with bone scan abnormalities, sug-
gesting that serum concentrations of the markers 
refl ect changes in the turnover in the tissues seen 
on bone scans.60 There have been reports of 
increased COMP levels in patients with familial OA 
from a mutation in the type II procollagen gene 
COL2A1 with a 100% concordance for the develop-
ment of OA.61 Higher serum COMP levels have 
been observed in patients with radiographic 
Kellgren-Lawrence Grades III–IV than in Grades 
I–II lesions,62 which may be due to the involvement 
of more joints in the later stages. Radiographs of 
the hands, knees, hips, and lateral lumbar spine were 
obtained, and the OA severity grade for each patient 
was based on the score for the most severely 
involved joint.61 In a chronic erosive arthritis model 
in rats, COMP levels correlated with the severity of 
macroscopically detectable arthritis at two different 
timepoints: on days 35 and 49 after induction of 
arthritis with pristane injection.63 Serum COMP also 
highly correlated with degree of histologic cartilage 
destruction in rats.64 In knee OA, serum COMP 
levels correlated with the clinical manifestation of 
synovitis, but not with the extent of joint damage.65 
Serum COMP was found to be a specifi c marker for 
the cartilage degradation in RA and not related to 
the nonspecifi c infl ammatory process, as there was 
a signifi cant difference in levels when compared to 
patients with other infl ammatory rheumatic diseases 
with less cartilage-destructive arthritis.66 However, 
sensitivity (15%–48%) and specifi city (66%–69%) 
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of COMP as a marker for RA was shown to be low 
in both selected and unselected cohorts with RA 
when compared to antibodies against cyclic 
citrullinated peptides (anti-CCP Ab).67
COMP as a Prognostic Indicator
There has also been evidence supporting COMP 
as a prognostic indicator. COMP levels were higher 
in patients with aggressive RA than in those with 
non-aggressive RA. Patients with aggressive RA 
were defi ned as those who required a total hip 
replacement within four years of disease onset.68–70 
This suggested that COMP might be a prognostic 
factor for large joint destruction. In other studies, 
although baseline levels were not predictive of 
knee joint destruction assessed by changes in joint 
space width over 5 years, an increase in serum COMP 
over 1 year71 or 3 years72 indicated progressive 
disease in early and established OA. Patients were 
labelled to have progressive disease if they had a 
joint space reduction of at least 2 mm on radiograph 
or if they received surgical intervention. In contrast, 
the elevation of serum COMP levels at baseline 
was associated with progression of symptomatic 
advanced hip OA. This was assessed by changes 
in radiographic joint space over 1 year measured 
with digitized image analysis.59 In patients with 
established knee OA, the change in joint space 
width over 3 years, summed for both knees, 
correlated positively with serum COMP levels. 
Patients who progressed by two Kellgren-Lawrence 
grades62 on their radiographs were shown to have 
had signifi cantly higher COMP levels at baseline 
as well as at the end of the study.73 In another series 
of patients with knee pain and tibiofemoral OA 
followed over 5 years, serum COMP was related 
to progressive joint damage. The serum COMP 
was higher in those with progression of OA, 
defi ned by an increase in joint space narrowing of 
at least 2 mm or by treatment with total joint 
replacement. The increased COMP was seen at 
baseline and each follow-up visit. Logistic 
regression analysis showed that on average, a 
1-unit increase in serum COMP levels increased 
the probability of radiographic progression by 
15%. Serum COMP also rose after joint replacement 
surgery and remained elevated for up to 12 months.74 
This suggests that sequential measurements of 
COMP levels can identify patients at high risk for 
radiological progression of OA. In patients with 
traumatic knee injury, it was found that a subgroup 
with elevated and increasing serum COMP levels 
were at increased risk for developing posttraumatic 
osteoarthritis.75 In patients with symptoms and 
clinical signs of hip and knee pathology, but no 
radiographic evidence OA, a statistically signifi cant 
association was found between serum COMP and 
hip-related symptoms, but not knee related symp-
toms.76 This would support the use of serum COMP 
as a biomarker of hip joint pathology prior to 
radiographic fi ndings. It is still not clear whether the 
baseline level or the short-term change in 
serum COMP levels is a better predictor of joint 
destruction.
COMP as a Therapeutic Indicator
In regards to the use of serum COMP to monitor 
the response to various therapies, there have been 
varying results. In patients with RA treated with 
TNF-alpha blockers infl iximab or etanercept, serum 
COMP decreased at 3 months of therapy and 
remained low at 6 months in responders and non-
responders.77 Basal levels of COMP in RA patients 
can predict the extent of clinical response to 
treatment with adalimumab, another TNF-alpha 
inhibitor.78 Patients with low COMP and CRP levels 
at baseline were also shown to have a very high 
American College of Rheumatology (ACR) 
70 response rate when treated with various anti-
TNF-alpha drugs, in contrast to patients with 
elevated COMP at baseline.79 An ACR 70 response 
requires a patient to have a 70% reduction in the 
number of swollen and tender joints, and a reduction 
of 70% in three of the following fi ve parameters: 
physician global assessment of disease, patient 
global assessment of disease, patient assessment of 
pain, C-reactive protein or erythrocyte sedimentation 
rate, and degree of disability in Health Assessment 
Questionnaire score.80 The results suggest that 
COMP level could be helpful in deciding whether 
continued observation or modifi cation in treatment 
is warranted in patients who may not be responding 
to their current treatment early on.79 No association 
between baseline COMP and change in COMP was 
found with joint space width or scores on the 
Western Ontario and McMaster Universities Osteo-
arthritis Index in a study of glucosamine sulfate for 
OA.81,82 However, postmenopausal women with 
rheumatoid arthritis receiving hormone replacement 
therapy (HRT) had lower serum COMP.83 In rats 
with collagen-induced arthritis treated with cortico-
steroid therapy, serum COMP levels remained 
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stable compared to increases in COMP over time 
in placebo-treated rats.64 Intra-articular glucocorti-
coid treatment for knee synovitis in RA patients 
reduces serum COMP, with a slightly larger decrease 
of serum COMP in the group randomized to 24 hour 
bed rest instead of normal activity.84 Serum levels 
of COMP were also used to monitor the therapy 
response to intravenous bolus steroid therapy in 
patients with active RA. The intravenous treatment 
with steroids had a rapid effect on decreasing serum 
COMP levels within 10 days.85 Thus, serum COMP 
is infl uenced by different therapies, and may be a 
valuable parameter for monitoring the treatment 
response in patients with arthritis.
Biological Variations of COMP
The normal time course of COMP and its variations 
will need to be further delineated before it may be 
used as a widespread biomarker of arthritis. In the 
Johnston County Osteoarthritis Project, a population-
based study of OA in African-Americans and 
Caucasians, ethnic and gender differences in COMP 
were not explained by differences in age, BMI, 
height, presence or severity of radiographic OA, or 
number of other symptomatic joints. In both ethnic 
groups, serum COMP increased with age and BMI, 
and was also higher in those with radiographic OA. 
African-American women had higher levels of 
COMP than Caucasian women and Caucasian men 
had higher COMP than Caucasian women.86 In a 
series of patients in Poland, a correlation was seen 
between serum COMP levels and age in patients 
with RA, but not OA. However, in OA patients, there 
was a correlation between the serum COMP level 
and Western Ontario and McMaster Universities 
(WOMAC) index pain scale for the lower limbs and 
the T-score value of densitometry examinations.87 
Serum levels of COMP are also affected by exercise, 
especially during the fi rst 30 minutes. Therefore, 
samples of blood for analysis of serum COMP 
should be drawn after at least 30 minutes rest.88 
Otherwise, during normal everyday activities, serum 
COMP levels are constant during the day between 
8 am and 9 pm. There is a substantial decrease in 
COMP at night, reaching the lowest levels between 
4 and 5 am, suggesting that COMP is eliminated 
rapidly once it reaches the bloodstream.89
Conclusions
Serum COMP has potential to be used as a 
biomarker of arthritis. Elevations in this marker 
have been associated with the presence of arthritis 
and can correlate with the severity of the disease. 
Elevated serum COMP levels have also been shown 
to predict OA progression. Certain therapies aimed 
at disease modifi cation in OA and RA can infl uence 
serum COMP levels, which in turn may refl ect 
cartilage damage. But standards of this marker will 
need to be established that consider ethnic and 
gender differences. Further clinical and longitudinal 
studies of ethnic and other variations in serum 
COMP and its association with arthritis symptoms 
and functional status would be of benefi t. The 
metabolism and clearance of COMP, as well as the 
contributions of non joint tissues to COMP serum 
levels, will also need to be determined. This 
information is needed to ascertain if an increase in 
the level of the marker indicates increased synthesis, 
increased breakdown or modifications of its 
clearance. Serum levels refl ect the release of COMP 
from all cartilage or bone structures and elimination 
at different points in its metabolism. The lack of 
specifi city of COMP for cartilage may limit its use 
in assessing changes in joint damage in OA/RA. 
Specifi c reagents for degraded COMP are lacking, 
and therefore have limited the usefulness of this 
marker to determine the presence of arthritis and 
to develop an assay with a dichotomous outcome 
(i.e. normal vs. abnormal for a population). In its 
current form, the assay is useful to monitor response 
to treatment in a given individual with infl ammatory 
arthritis. The assay may need to be complemented 
by radiographic or MRI evaluations. However, 
COMP would be a valuable tool for identifying 
patients at high risk for rapid joint destruction and 
for monitoring treatment effi cacy.
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